{"result": {"id": "d576f6b8-6a86-4a6a-b82c-e1553726a806", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>中华全科医师杂志<|>ORGANIZATION<|>A medical journal that published guidelines on hypertension treatment in April 2019)\n##\n(\"entity\"<|>CCB钙通道阻滞剂<|>ORGANIZATION<|>A class of antihypertensive drugs including dihydropyridine calcium channel blockers)\n##\n(\"entity\"<|>ACEI血管紧张素转换酶抑制剂<|>ORGANIZATION<|>Angiotensin-converting enzyme inhibitors used for hypertension treatment)\n##\n(\"entity\"<|>ARB血管紧张素Ⅱ受体拮抗剂<|>ORGANIZATION<|>Angiotensin II receptor blockers used for hypertension treatment)\n##\n(\"entity\"<|>氨氯地平<|>ORGANIZATION<|>A specific CCB drug (amlodipine) approved for hypertension and coronary artery disease)\n##\n(\"entity\"<|>非洛地平<|>ORGANIZATION<|>A specific CCB drug (felodipine) used for hypertension treatment)\n##\n(\"entity\"<|>螺内酯<|>ORGANIZATION<|>A potassium-sparing diuretic used in resistant hypertension)\n##\n(\"entity\"<|>β受体阻滞剂<|>ORGANIZATION<|>Beta-blockers recommended for hypertension with stable angina)\n##\n(\"entity\"<|>襻利尿剂<|>ORGANIZATION<|>Loop diuretics used in advanced renal impairment)\n##\n(\"relationship\"<|>CCB钙通道阻滞剂<|>氨氯地平<|>Amlodipine is a specific medication in the CCB class<|>9)\n##\n(\"relationship\"<|>CCB钙通道阻滞剂<|>非洛地平<|>Felodipine is a specific medication in the CCB class<|>9)\n##\n(\"relationship\"<|>ACEI血管紧张素转换酶抑制剂<|>ARB血管紧张素Ⅱ受体拮抗剂<|>Both are RAAS-blocking antihypertensive drug classes<|>7)\n##\n(\"relationship\"<|>β受体阻滞剂<|>CCB钙通道阻滞剂<|>Both are first-line treatments for hypertension with coronary artery disease<|>8)\n##\n(\"relationship\"<|>螺内酯<|>襻利尿剂<|>Both are diuretics used in different stages of renal impairment for hypertension<|>6)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752165544, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 520, "prompt_tokens": 2948, "total_tokens": 3468, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 2560}, "prompt_cache_hit_tokens": 2560, "prompt_cache_miss_tokens": 388}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: +\t±\t\n血脂异常\t±\t+\t+\t\t\n　　注：CCB钙通道阻滞剂(二氢吡啶类);ACEI血管紧张素转换 酶抑制剂；ARB血管紧张素Ⅱ受体拮抗剂；+适用；-证据不足或不 适用；±可能适用；对伴心肌梗死病史者可用长效CCB控制高血 压；氨氯地平和非洛地平可用；冠心病二级预防；螺内酯；估算 的肾小球滤过率<30ml·min1·(1.73m2)-1时应选用襻利尿剂\n\n中华全科医师杂志2019年4月第18卷第4期Chin JGen Pract,April 2019.Vol.18,No.4                                      ·307·\n\n\n　　3.联合治疗：联合应用降压药物已成为降压治 疗的基本法33。为达到目标血压水平，大部分高血 压患者需用2种或以上降压药物。高血压联合治 疗方案见图3。\n　　　4.特殊人群的降压治疗方案：特殊人群主要包 括老年和有合并症的患者。近期在一些有合并症 高危高血压患者的研究显示，强化降压治疗(诊室 SBP<130mmHg) 对包括老年患者在内的高危的高 血压患者可减少心血管并发症和总的死亡，但同时 不良反应也有增加趋势。应注意年龄增高并不是 设定更高降压目标的充分条件，对于老年和有合并 症的患者，医生应根据患者合并症的严重程度，对 治疗的耐受性及坚持治疗的可能性进行评估，综合 决定患者的降压目标。\n( 1 ) 老 年 高 血 压 ：\n\n　\n\n\n\n(2)高血压合并卒中：\n\n要点：高血压合并卒中\n● 病情稳定的合并卒中患者，SBP≥140mmHg  和/或DBP≥90 mmHg时应启动降压治疗，降压目标为<140/90 mmHg。\n●急性缺血性合并卒中并准备溶栓者的血压应控制在<180/110mmHg。\n● 急性脑出血的降压治疗：SBP>220mmHg  时，应积极使用静脉 降压药物降低血压；患者SBP>180mmHg 时，可使用静脉降压 药物控制血压，160/90mmHg可作为参考的降压目标值。\n(3)高血压合并冠心病：\n要点：高血压合并冠心病\n●推荐<140/90 mmHg 作为合并冠心病的高血压患者的降压目 标，如能耐受，可降至<130/80 mmHg, 应注意DBP不宜降得过 低[36-37]。\n●稳定性心绞痛的降压药物应首选β受体阻滞剂或CCB。\n(4)高血压合并心力衰竭：\n\n　\n(5)高血压合并肾脏疾病：\n\n\n　\n\n\n\n( 7 ) 难 治 性 高 血 压 ：\n\n要点：难治性高血压\n●确定患者是否属于难治性高血压常需配合采用诊室外血压 测量。\n●寻找影响血压控制不良的原因和并存\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>中华全科医师杂志<|>ORGANIZATION<|>A medical journal that published the guidelines on hypertension treatment in April 2019, Volume 18, Issue 4)\n##\n(\"entity\"<|>CCB钙通道阻滞剂<|>ORGANIZATION<|>A class of drugs used to control hypertension, specifically dihydropyridine calcium channel blockers)\n##\n(\"entity\"<|>ACEI血管紧张素转换酶抑制剂<|>ORGANIZATION<|>A class of drugs used to treat hypertension and heart failure, known as angiotensin-converting enzyme inhibitors)\n##\n(\"entity\"<|>ARB血管紧张素Ⅱ受体拮抗剂<|>ORGANIZATION<|>A class of drugs used to treat hypertension, known as angiotensin II receptor blockers)\n##\n(\"entity\"<|>氨氯地平<|>ORGANIZATION<|>A specific dihydropyridine calcium channel blocker used to control hypertension)\n##\n(\"entity\"<|>非洛地平<|>ORGANIZATION<|>Another specific dihydropyridine calcium channel blocker used to control hypertension)\n##\n(\"entity\"<|>螺内酯<|>ORGANIZATION<|>A diuretic used in the treatment of hypertension and heart failure)\n##\n(\"entity\"<|>β受体阻滞剂<|>ORGANIZATION<|>A class of drugs used to treat hypertension, particularly in patients with stable angina)\n##\n(\"relationship\"<|>CCB钙通道阻滞剂<|>氨氯地平<|>AmLodipine is a specific drug within the CCB class<|>8)\n##\n(\"relationship\"<|>CCB钙通道阻滞剂<|>非洛地平<|>Felodipine is a specific drug within the CCB class<|>8)\n##\n(\"relationship\"<|>ACEI血管紧张素转换酶抑制剂<|>ARB血管紧张素Ⅱ受体拮抗剂<|>Both are classes of drugs used to treat hypertension but through different mechanisms<|>5)\n##\n(\"relationship\"<|>β受体阻滞剂<|>CCB钙通道阻滞剂<|>Both are recommended for treating hypertension in patients with stable angina<|>6)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_a917537f3c3ae2f505e8cf2696dcbfbbf2fa625ee076ff0d9b3b4a7d0dfdfa3e_v2"}